Clinical Trial Update: ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Advair Diskus (fluticasone propionate/salmeterol) with Serevent Diskus (salmeterol) in chronic obstructive pulmonary disease, focusing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)
• SEREVENT DISKUS (SALMETEROL XINAFOATE)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: TERMINATED